BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - September 12, 2014) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Office of New Drugs (OND) within the U.S. Food and Drug Administration (FDA) has denied Amarin's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement.
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that
new scientific data presented at the MS Boston 2014: Joint
ACTRIMS-ECTRIMS Meeting reveals differences in the gene expression
profile between COPAXONE ® (glatiramer acetate injection) and
other glatiramer acetate products.
Glatfelter (NYSE: GLT) today announced it has signed a definitive
agreement to purchase all of the outstanding equity of
Spezialpapierfabrik Oberschmitten GmbH (SPO) from FINSPO
Beteiligungs-GmbH for €8.5 million (approximately U.S.$11 million). SPO
has annual sales of approximately €25 million (U.S.$33 million).
“This acquisition will further our Composite Fibers business unit’s
strategy of capitalizing on the fast-growing electrical market by
expanding our electrical papers product platform,” said Dante C.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.